Antimykotika – neue Substanzen, neue Erfahrungen

Zusammenfassung

Bei hämatologisch-onkologischen Patienten, Organtransplantierten, Intensivtherapiepatienten und Frühgeborenen steigt die Inzidenz der durch Pilze hervorgerufenen lebensbedrohlichen Infektionen. Die Letalität invasiver Pilzinfektionen, beispielsweise bedingt durch eine Aspergillus-Spezies oder durch Mukormyzeten, kann bis zu 100 % betragen. Trotz aktueller Verbesserungen der Diagnostik und Therapie [1], [2], [3] ist eine effektive antimykotische Prophylaxe nur für wenige Patientengruppen validiert. Umfassende Kenntnisse der spezifischen Diagnostik und aktueller Therapie-Algorithmen sind bei der Behandlung invasiver Pilzinfektionen unerlässlich.

Abstract

The incidence of life threatening invasive fungal infections in patients with hematological malignancies during intensive chemotherapy or after hematopoetic stem cell transplantation, patients after solid organ transplantation, ICU patients and premature infants is rising. Mortality rates of invasive fungal infections, caused by Aspergillus species or mucormycetes, may reach 100%, in spite of considerable progress in diagnosis, antifungal prophylaxis and therapy. Comprehensive, profound knowledge of specific diagnostic and current treatment algorithms is essential to improve the prognosis of patients suffering from systemic fungal infections; this article encompasses recent developments in the field of antifungal treatment.

Schlüsselwörter

Antimykotika - Prophylaxe - Therapie - invasive Pilzinfektion

Keywords

antifungal prophylaxis - antifungal treatment - invasive fungal infections

• Literatur

• 1 Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015; 373: 1445-1456
• 2 Pappas PG, Kauffman CA, Andes DR et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62: 409-417
• 3 Patterson TF, Thompson GR, 3rd Denning DW. et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63: e1-e60
• 4 Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297
• 5 Groll AH, Silling G, Young C et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2010; 54: 4143-4149
• 6 Heinz WJ, Buchheidt D, Ullmann AJ. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections. Mycoses 2016; 59: 480-493
• 7 Marr KA, Schlamm HT, Herbrecht R et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162: 81-89
• 8 López-Cortés LE, Almirante B, Cuenca-Estrella M et al. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. Clin Microbiol Infect 2016; 22: 733.e1-8
• 9 Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci 2015; 1354: 1-11
• 10 Luong ML, Al-Dabbagh M, Groll AH et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother 2016; 71: 1786-1799
• 11 Dekkers BGJ, Bakker M, van der Elst KCM et al. Therapeutic Drug Monitoring of Posaconazole: an Update. Curr Fungal Infect Rep 2016; 10: 51-61
• 12 Maertens JA, Raad II, Marr KA et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016; 387: 760-769
• 13 Marty FM, Ostrosky-Zeichner L, Cornely OA et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016; 16: 828-837
• 14 Verweij PE, Chowdhary A, Melchers WJ et al. Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?. Clin Infect Dis 2016; 62: 362-368
• 15 Steinmann J, Hamprecht A, Vehreschild MJ et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015; 70: 1522-1526
• 16 Ashbee HR, Barnes RA, Johnson EM et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69: 1162-1176